Tethys Bioscience, an Emeryville, CA-based developer of tests supporting the identification of chronic diseases such as diabetes, has closed a $25m Series D round of financing.
The round was led by aeris CAPITAL AG with participation from new investor Wasatch Advisors.
Existing investors MDV-Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers and Intel Capital also participated in the round.
The funds will be used to commercialise Tethys Bioscience’s PreDx™ Diabetes Risk Score (DRS) product, a blood test that support clinicians in identifying patients at highest risk of developing type 2 diabetes within five years.
In conjunction with the financing, George Rehm, Managing Partner of aeris CAPITAL, will join the company’s Board of Directors.